XML 28 R6.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended 27 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2023
Cash Flows Used In Operating Activities        
Net Loss $ (32,273,128) $ (73,538,157) $ (50,149,077)  
Non-Cash Adjustments        
Depreciation and Amortization 3,149,924 3,930,169 4,931,692  
Stock-Based Compensation 5,330,306 11,565,374 12,711,084  
Impairment of Patents and Trademarks 0 0 41,869  
Loss on Fixed Asset Disposal 106,898 27,654 0  
Allowance for Credit Losses   977,363 1,574,000  
Inventory Reserves for Obsolescence 503,400 4,167,917 4,358,062  
Impairment on Goodwill, Intangible Assets, and Equity Investments 400,000 30,301,355 2,136,993  
(Increase) Decrease in Operating Assets        
Accounts Receivable (17,917) 1,240,605 (1,842,715)  
Accrued Revenues in Excess of Billings 139,833 (507,727) 103,358  
Other Receivables (379,615) 208,271 258,434  
Inventories 2,121,076 19,287 (2,090,523)  
Manufacturing Vendor Prepayments 115,991 31,720 594,870  
Prepaid Expenses and Other Assets 7,702 271,399 167,837  
Increase (Decrease) in Operating Liabilities        
Accounts Payable 146,789 (1,032,409) 358,883  
Accrued Expenses 1,881,659 (1,470,691) 745,904  
Unearned Revenue (63,540) 107,062 (10,225)  
Income and Other Taxes Payable 41,350 (38,564) (168,270)  
Net Cash Flows Used in Operating Activities (18,789,272) (23,739,372) (26,277,824)  
Cash Flows Used in Investing Activities        
Purchases of Fixed Assets (2,013,454) (1,358,991) (5,323,483)  
Investments in Patents and Trademarks (554,816) (560,958) (632,483)  
Investments in Licenses   (1,000,000) (10,500,000)  
Investments in Software Development     (125,000) $ (500,000)
Investment in Atomistic     (2,500,000)  
Investments in Other Equity Assets (50,000)   (200,000)  
Net Cash Flows Used in Investing Activities (2,618,270) (2,919,949) (19,280,966)  
Cash Flows Provided by (Used in) Financing Activities        
Proceeds from Sale of Preferred and Common Stock to Quanta 10,000,000 10,000,000    
Proceeds from Exercise of Stock Options 106,843 110,760 21,196  
Proceeds from ATM Program, Net 14,286,816 8,179,475    
Purchase of Treasury Stock     (470,757)  
Net Cash Flows Provided by (Used in) Financing Activities 24,371,250 18,290,235 (449,561)  
Net Increase (Decrease) in Cash and Cash Equivalents 2,963,707 (8,369,086) (46,008,351)  
Cash and Cash Equivalents - Beginning of Period 18,186,506 26,555,592 72,563,943  
Cash and Cash Equivalents - End of Period 21,150,213 18,186,506 26,555,592 $ 26,555,592
Supplemental Disclosures        
Non-Cash Investment in Licenses     1,000,000  
Investment in Atomistic - Equity issued   181,675 3,284,126  
Accrued Preferred Dividends included in Accrued Expenses 39,923      
Depreciation and Amortization included in Research and Development Expense 869,361 201,070 201,147  
Stock-Based Compensation Expense - Expensed less Previously Issued     $ 92,454  
Purchases of Fixed Assets included in Accrued Expenses 723,023      
Series B Preferred Stock        
Cash Flows Provided by (Used in) Financing Activities        
Preferred Dividends Paid $ (22,409) $ 0